French pharmaceutical company AB Science (Euronext Paris:AB) announced on Monday that the European Medicines Agency (EMA) has approved a shelf-life extension for its veterinary drug Masivet, increasing it from 36 to 48 months.
This approval applies specifically to the 50mg tablet formulation currently available in the European Union.
Masivet is indicated for the treatment of non-resectable Grade 2 or 3 mast cell tumours in dogs with confirmed c-kit tyrosine kinase receptor mutations. The product is marketed by AB Science and is accessible in all EU member states.
The extended shelf life enhances inventory flexibility for AB Science, veterinary caregivers and patients. It also reduces the risk of product expiration and supports uninterrupted access to treatment.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval